Abstract:Background: Tyrosine kinase inhibitor (TKI) dose optimization is important to maintain efficacy and mitigate adverse events for chronic myeloid leukaemia (CML) patients. However, the impact of low-dose TKI therapy on outcomes after achieving a major molecular response (MMR) remains undetermined. Aims: To compare the achievement of deeper molecular responses and maintenance of previous responses between low-dose and full-dose TKI therapy after achieving MMR. The factors associated with loss of MMR or MR4 after dose reduction were further explored. Methods: This was a retrospective analysis including adults with chronic or accelerated phase CML who received low-dose or full dose of imatinib, nilotinib or dasatinib after MMR was achieved during the administration of the full-dose TKI. BCR::ABL1 transcript were analyzed using standard real-time quantitative polymerase chain reaction (qPCR) every three months and droplet digital PCR (ddPCR) at the time of dose reduction. The outcomes were compared between low-dose group and full-dose group after landmark analysis and propensity score matching. Multivariate analysis was performed using a Cox’s regression model to identify the factors associated with MMR and MR4 failure-free survival after dose reduction. Results: Consecutive subjects with CML (n=837) in the chronic or accelerated phase who achieved an MMR with initial TKI therapy were analysed; 271 subjects received low-dose TKI therapy at a median of 31 months (IQR, 11–58 months) after achieving a MMR, of whom 230 (85%) were on imatinib, 34 (12%) on nilotinib and 7 (3%) on dasatinib. Subjects in the low-dose group were older (P<0.001), had a higher proportion of accelerated phase at diagnosis (P=0.002), a shorter interval from the start of TKI therapy to achieving a MMR (P<0.001) and a longer duration of follow-up (P<0.001). Landmark analysis and propensity score matching indicated that low-dose TKI therapy had no impact on the 6-year cumulative incidence of MR4 (75% [59, 91%] versus 66% [57, 76%]; P = 0.489), MMR failure-free survival rates (98% [96, 100%] versus 95% [91, 99%]; P = 0.351), MR4 failure-free survival rates (92% [87, 97%] versus 93% [87, 99%]; P = 0.815), progression-free survival (100% versus 99% [98, 100]; P = 0.311) or survival (100% versus 99% [97, 100]; P = 0.236) compared with full-dose TKI therapy, but a lower cumulative incidence of MR4.5 (43%, [31, 56%]) versus 61%, [53, 70%]; P = 0.029) was observed. In 271 subjects receiving low-dose TKI therapy, the MMR and MR4 failure-free survival rates at 6 years were 95% (95% CI: 93, 98%) and 89% (84, 94%), respectively. Multivariate analyses showed age ≥60 years (HR, 3.6; 95% CI [1.1, 11.1]; P=0.029) and BCR::ABL1IS >0.0078% detected by qPCR (4.4 [1.4, 13.9]; P=0.012) at the time of dose reduction were associated with reduced MMR failure-free survival. In 237 subjects with data of ddPCR, age ≥60 years (HR, 4.8 [1.3, 17.0]; P=0.016) and BCR::ABL1IS >0.0032% detected by ddPCR (10.8 [1.4, 85.7]; P=0.025) were associated with reduced MMR failure-free survival. BCR::ABL1IS >0.0048% detected by qPCR (HR, 2.3 [1.0, 5.3]; P = 0.049) or BCR::ABL1IS >0.0029% detected by ddPCR was associated with reduced MR4 failure-free survival. Summary/Conclusion: Post-MMR low-dose TKI therapy had comparable outcomes with full-dose therapy in CML patients. Older age and not achieving MR4 before dose reduction had a higher likelihood of MMR loss.Figure 1 (A) Cumulative incidence of MR4, (B) cumulative incidence of MR4.5, (C) MMR failure-free survival and (D) MR4 failure-free survival between full-dose group and low-dose group after landmark analysis and propensity score matching analysis. Keywords: Chronic myeloid leukemia, Tyrosine kinase inhibitor, Droplet Digital PCR (ddPCR)

[Analysis of Efficacy and Related Factors of Acquired Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with TKI].

The Treatment of Patients with Chronic Myeloid Leukemia Chronic Phase Combined with Myelofibrosis with Tyrosine Kinase Inhibitors: A Chinese Population-Based Study.

Early BCR-ABL1 Decline in Imatinib-Treated Patients with Chronic Myeloid Leukemia: Results from a Multicenter Study of the Chinese CML Alliance

Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia

P684: a multicenter retrospective study in china: clinical characteristics and prognosis of patients with cml-cp treated with different tyrosine kinase inhibitors

S158: EFFICACY OF LOW-DOSE TYROSINE KINASE INHIBITOR THERAPY AFTER ACHIEVING MAJOR MOLECULAR RESPONSE IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA

[Clinical Effect of Tyrosine Kinase Inhibitors in the Treatment of P230 Chronic Myeloid Leukemia].

Predictive Value of Molecular Response after Treatment with Tyrosine Kinase Inhibitor for 3 Months in Patients with Chronic Myeloid Leukemia

[Clinical Efficacy of Second-generation Tyrosine Kinase Inhibitor in Treating Chronic Myeloid Leukemia].

Deep Molecular Response Rate In Chronic Phase Chronic Myeloid Leukemia: Elegibility To Discontinuation Related To Time To Response And Different Frontline Tki In The Experience Of The Gimema Labnet Cml National Network

Efficacy of Tyrosine Kinase Inhibitor in Treatment of Chronic Myeloid Leukemia Patients

18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China

Efficacy analysis of imatinib in treatment of patients with chronic myeloid leukemia

Targeted Next-Generation Sequencing Identifies Additional Mutations Other than <i>BCR proportion ABL</i> in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study

Investigation of Long-Term Follow-Up Results of 135 Patients with Chronic Myeloid Leukemia Receiving Imatinib

Molecular Responses of Late Chronic Phase Chronic Myeloid Leukemia Patients after Achieving Complete Cytogenetic Responses with Imatinib Treatment: a 6-Year Follow-Up

Analysis of the Efficacy and Influencing Factors of Nilotinib or Dasatinib As Second- or Third-Line Treatment in Patients with Chronic Myeloid Leukemia in the Chronic Phase and Accelerated Phase

[Analysis of Efficacy and Related Factors in 85 Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate].

Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia

Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response

Second-Generation Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response: A Systematic Review and a Meta-Analysis